Replies to post #20326 on BioCurex, Inc.(fka BOCX)

[Kag]

Gyro, the evidence seems to make the dots more diverging than converging.

Biosite has had its hands on RECAF for approximately a year and then a patent application for “Measuring Canine BNP and Uses Thereof” is filed on March 5, 2009. Then last week BioCurex has its own press release for OncoPet.

Dr. Ogilvie (a world expert in veterinary oncology) commented yesterday that "the disease is too diverse for one marker. That is why gene chips (multiarray technology) is likely to be the screening test of the future, however, even that has serious sensitivity and specificity issues. The cost to the medical system is huge to weed out the real diagnosis if sensitivity and specificity is not good.”
kag